Saroglitazar

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Burden of Primary biliary cholangitis

9 evidence topics · 10 sources

Economic impact of diagnostic testing

No evidence found.